We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
- Authors
Sládek, Norman E; Kollander, Rahn; Sreerama, Lakshmaiah; Kiang, David T
- Abstract
In preclinical models, established molecular determinants of cellular sensitivity to cyclophosphamide, long a mainstay of chemotherapeutic regimens used to treat breast cancers, include the aldehyde dehydrogenases that catalyze the detoxification of this agent, namely, ALDH1A1 and ALDH3A1. As judged by bulk quantification of relevant catalytic activities, as well as of relevant proteins (ELISAs), tissue levels of these enzymes vary widely in primary and metastatic breast malignancies. Thus, interindividual variation in the activity of either of these enzymes in breast cancers could contribute to the wide variation in clinical responses obtained when such regimens are used to treat these malignancies. Direct evidence for this notion was sought in the present investigation.
- Publication
Cancer chemotherapy and pharmacology, 2002, Vol 49, Issue 4, p309
- ISSN
0344-5704
- Publication type
Journal Article
- DOI
10.1007/s00280-001-0412-4